Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)

Clinical trial NCT05482295 · NOT_YET_RECRUITING

Trial details

NCT number: NCT05482295
Sponsor: PT Bio Farma
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Vaccine Reaction Vaccine Adverse Reaction

Start date: 2025-09-01
Primary completion: 2026-05-01
Enrollment: 540

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.